Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

65.70EUR
20 Apr 2018
Change (% chg)

€-0.26 (-0.39%)
Prev Close
€65.96
Open
€66.04
Day's High
€66.30
Day's Low
€65.44
Volume
1,495,452
Avg. Vol
1,526,431
52-wk High
€80.07
52-wk Low
€58.96

Latest Key Developments (Source: Significant Developments)

Fresenius says US Tax Reform ‍results In One-Time Book Gain Of about 90 mln euros
Saturday, 23 Dec 2017 

Dec 22 (Reuters) - Fresenius Se ::‍NEW US TAX LEGISLATION TRIGGERS REVALUATION OF DEFERRED TAX LIABILITIES​.US TAX REFORM ‍RESULTS IN A ONE-TIME BOOK GAIN OF APPROXIMATELY EUR 90 MILLION, TO BE REFLECTED IN FRESENIUS' 2017 GROUP NET INCOME​.‍WILL REPORT FY17 RESULTS, PROVIDE FY18 GUIDANCE, INCLUDING DETAILS ON RECURRING TAX EFFECTS RESULTING FROM US TAX REFORM, ON FEB 27, 2018​.  Full Article

Fresenius says Q2 adj EBIT up 8 pct
Tuesday, 2 Aug 2016 

Fresenius Se : Says q2 adj ebit 1,051 million eur . Says q2 sales 7.1 billion eur (+2%, +5% in constant currency) . Says q2 adj net income 393 million eur . Reuters poll average for fresenius q2 sales was 7.16 billion eur, adjusted ebit 1.05 billion, adjusted net income 382 million Further company coverage: [FREG.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

FMC sticks to guidance after Q2 results
Tuesday, 2 Aug 2016 

Fresenius Medical Care AG : Says q2 ebit $641 million . Says q2 net income $294 million . Says q2 sales $4,420 million . Reuters poll average for fmc q2 net revenue was $4.44 billion, ebit $634 million, net income $284 million .Says despite unfavorable foreign currency developments and continuous cost pressure, we are confident we will achieve our full year guidance.  Full Article

Fresenius SE & Co KGaA confirms FY 2016 guidance
Tuesday, 3 May 2016 

Fresenius SE & Co KGaA:Confirms its guidance for FY 2016; Sales are expected to increase by 6 pct to 8 pct in constant currency. Net income is expected to grow by 8 pct to 12 pct in constant currency.  Full Article

Photo

Fresenius spokesman says probe into target Akorn continues

FRANKFURT Fresenius said on Tuesday its investigation into potential breaches of U.S. Food and Drug Administration data requirements at takeover target Akorn was ongoing.